• AVONEX has over 23 years’ experience of demonstrated efficacy and real-world safety data1-10
  • AVONEX has an established, manageable tolerability and safety profile1
  • AVONEX is a convenient once-a-week IM injection1
  • If clinically needed, the use of AVONEX may be considered during pregnancy and breast-feeding.1

Indication1

AVONEX is indicated for the treatment of

Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three-years without evidence of continuous progression between relapses; AVONEX slows the progression of disability and decreases the frequency of relapses.

Patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis.1

Biogen- 51788. Date of preparation: May 2020